Backed by broad syndicate, Mediar takes downstream approach to fibrosis

Academic spinout has drawn $105M to advance first-in-class therapies against three targets

Spun out of Mass General and Brigham and Women’s hospitals, newly launched Mediar will deploy $105 million to develop antibodies against three targets associated with myofibroblasts, taking a new approach to treating fibrosis.

A syndicate in which four large pharmas are represented alongside six other investors has supplied $85 million in series A funding, plus $20 million in prior seed capital, to five-year-old Mediar Therapeutics Inc.

Access the article on (paywall)